

Tilgotamab

Cat. No.:	HY-P99559
CAS No.:	2109731-10-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tilgotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilgotamab specifically binds to and activates DR5. Tilgotamab can be used for the research of multiple myeloma (MM) ^[1] .
In Vivo	Tilgotamab (20 µg/mL; 24 h) induces potent cytotoxicity of primary MM cells ^[1] . Tilgotamab is a mixture of 2 noncompeting DR5-specific immunoglobulin G1 (IgG1) antibodies, each with an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, resulting in antibody hexamerization, followed by Fc γR-independent clustering of DR5 molecules ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Horst HJ, et, al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA